Bacterial choline degradation in the human gut has been associated with cancer and heart disease. In addition, recent studies found that a bacterial microcompartment is involved in choline utilization by and species. However, many aspects of this process have not been fully defined. Here, we investigate choline degradation by the uropathogen 536. Growth studies indicated 536 degrades choline primarily by fermentation. Electron microscopy indicated that a bacterial microcompartment was used for this process. Bioinformatic analyses suggested that the choline utilization () gene cluster of 536 includes two operons, one containing three genes and a main operon of 13 genes. Regulatory studies indicate that the gene encodes a positive transcriptional regulator required for induction of the main operon in response to choline supplementation. Each of the 16 genes in the cluster was individually deleted, and phenotypes were examined. The ,, ,, ,, , and genes were required for choline degradation, but the remaining genes of the cluster were not essential under the conditions used. The reasons for these varied phenotypes are discussed. Here, we investigate choline degradation in 536. These studies provide a basis for understanding a new type of bacterial microcompartment and may provide deeper insight into the link between choline degradation in the human gut and cancer and heart disease. These are also the first studies of choline degradation in 536, an organism for which sophisticated genetic analysis methods are available. In addition, the gene cluster of 536 is located in pathogenicity island II (PAI-II) and hence might contribute to pathogenesis.